Navigation Links
On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
Date:2/19/2008

ANN ARBOR, Mich., Feb. 19 /PRNewswire/ -- Compendia Bioscience, Inc. today announced results of a second productive year, including a renewed and expanding commitment from all major customers and the addition of several "Top 20" oncology drug companies to its customer roster. The new customers and existing customer commitment expansions led to a greater than 300% revenue increase, with similar growth forecasted for 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO )

A key factor in Compendia's financial growth in 2007 was the mid-year release of Oncomine(TM) Concepts Edition, a unique analysis approach using drug and pathway signatures to help drug researchers and developers better understand a specific drug's biology and predict tumor populations likely to respond to the drug. Additionally, Compendia significantly expanded the Oncomine gene expression database in 2007 with cell line panels and drug perturbation studies, areas of specific interest for its customers.

"The addition of Oncomine Concepts Edition and targeted expansion of our data collection and curation efforts were key to our sales success last year, and multi-year commitments from customers have positioned us well for 2008 and beyond," said John Freshley, Compendia's Chief Business Officer. "We are particularly proud that we now count 12 of the top 20 oncology companies as our customers and are in active discussions with several more."

In addition, a major product milestone was completed in 2007 with the transition of the free academic offering from the University of Michigan to Compendia. With more than 15,000 user registrations, Oncomine has long been a leading tool for academic and non-profit researchers.

"This was a very significant step for Compendia," commented co-founder and CEO Dan Rhodes. "We have actively developed exciting new features for Oncomine within Compendia and the only practical way to guarantee academic community access to these features was to take full responsibility for website support and data delivery."

"It was a big investment in both time and money, but it has always been critical to us that the academic communities have the same research capabilities as our corporate customers. We are proud that many of these new capabilities are still provided under a free research license," continued John Freshley. "Some advanced custom analyses require a license to Oncomine Research Premium Edition, but this modest investment is a tremendous value given the groundbreaking research that we and others have been able to accomplish using the premium features."

Along with expanded and new customer commitments, Compendia received an additional financial boost in 2007 when awarded a $2.4 million dollar SBIR Fast-Track award from the National Cancer Institute.

"This award was terrific validation of our approach and will allow us to truly scale the Oncomine platform in the future," said Dan Rhodes. "We have already completed the phase I feasibility portion of the award and are looking forward to rapidly executing the rest of the project."

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. http://www.compendiabio.com

About Oncomine(TM)

Oncomine(TM) combines a rapidly growing compendium of 24,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates rapid and reliable biomarker and therapeutic target discovery, validation, and prioritization. http://www.compendiabio.com/products/products.htm


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Tapestry Reports Second Quarter 2007 Results
3. Callisto Reports on Second-Quarter 2007 Milestones
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
11. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/13/2017)...   OrthoAtlanta has been named the official orthopedic ... (AFHC) for the 2018 College Football Playoff (CFP) National Championship ... Stadium in Atlanta, Georgia . OrthoAtlanta is ... campaign, participating in many activities leading up to, and including ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
Breaking Medicine News(10 mins):